首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1736621

全球氧氣療法市場規模：依產品、行動用途、應用、地區、預測

Global Oxygen Therapy Market Size By Product, By Portability, By Application, By Geographic Scope And Forecast

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

氧氣療法市場規模及預測

2024 年氧氣療法市場規模價值 160.7 億美元，預計到 2032 年將達到 382.6 億美元，2026 年至 2032 年的複合年成長率為 11.45%。

氧氣療法是治療方法。氧氣療法可以使用多種設備進行，包括氧氣鼻管、面罩和人工呼吸器。

氧氣療法用於治療慢性阻塞性肺病(COPD)、肺炎、氣喘、心臟衰竭，並在手術期間提供足夠的氧氣。

此外，它們在重症加護環境中至關重要，可以改善血氧飽和度，減輕呼吸急促和疲勞等症狀，並穩定和支持患有嚴重呼吸和心臟疾病的患者。

全球氧氣療法市場動態

影響氧氣療法市場的關鍵市場動態是：

關鍵市場促進因素

呼吸系統疾病盛行率不斷上升：慢性呼吸系統疾病盛行率不斷上升是氧氣療法市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，2019 年全球有 3.91 億人患有慢性阻塞性肺病)。 COPD 是全球第三大死因，2019 年導致 323 萬人死亡。根據美國肺臟協會的數據，2020 年將有 3,730 萬美國人（占美國成年人的 11.5%）罹患慢性肺病。氣喘影響 2500 萬美國人，其中 510 萬是兒童。

人口老化：隨著世界人口老化，預計氧氣療法需求將會增加。根據聯合國經濟和社會事務部的報告，到2050年，65歲及以上人口的數量預計將達到15億人。到2050年，全球每六人就有一人年齡在65歲或以上，高於2019年的每十一人中就有一人。根據美國人口普查局的數據，過去十年，美國65歲及以上人口數量增加了三分之一以上（34.2%）。到2030年，所有嬰兒潮世代都將年滿65歲或以上，老年人口將增加到每五人中就有一人。

氧氣輸送系統的技術進步：攜帶式和家用氧氣療法設備的技術創新正在推動市場擴張。根據美國食品藥物管理局(FDA) 的數據，2015 年至 2020 年間，已有 50 多種新型氧氣療法設備或對現有設備的重大改進獲得批准。發表在《呼吸照護》雜誌上的一項研究發現，在接受長期氧氣療法受益人中，攜帶式氧氣濃縮機的使用率從 2009 年的 11.5% 上升到 2018 年的 43.5%。

主要挑戰

高成本：氧氣濃縮機、氧氣瓶、補充裝和耗材消耗了大量病患。這種經濟負擔導致他們推遲或錯過必要的治療，最終導致健康狀況不佳。在醫療資源匱乏的地區，基礎設施薄弱和缺乏補貼阻礙了病患獲得負擔得起的氧氣療法。

報銷挑戰：氧氣治療的報銷政策複雜，因付款方、患者病情和設備而異。這種缺乏一致性的情況使核准流程複雜化，延誤了報銷，並對患者的治療結果產生了負面影響。繁瑣的備案要求和精準的報銷限制造成了不確定性，使醫療保健提供者難以規劃和預算氧氣治療服務，從而限制了市場的成長。

主要趨勢

轉型為居家照護：隨著可攜式濃縮器和遠端監控技術的發展，氧氣療法市場正在轉型為居家照護。這種轉變減少了醫院再入院率，並鼓勵以患者為中心的治療方式，使患者在家中接受氧氣療法變得更容易、更經濟。

遠端醫療整合：遠端醫療在氧氣治療管理中的重要性日益提升，因為它能夠遠端監測患者的生命徵象、血氧水平和治療依從性。及早發現問題並進行遠距會診，可以提高患者獲得專科護理的機會，解決問題，從而改善患者預後，減少併發症。

注重舒適便利：市場優先考慮易於使用且舒適的氧氣輸送系統。更輕盈、更安靜、更隱密的製氧機和麵罩正在研發中，以提高患者的舒適度和便利性，從而提高需要氧氣療法患者的治療依從性和生活品質。

Increasing Prevalence of Respiratory Diseases: The increased prevalence of chronic respiratory disorders is a significant driver of the oxygen therapy market. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) impacted 391 million individuals worldwide in 2019. COPD is the world's third greatest cause of death, with 3.23 million deaths in 2019. According to the American Lung Association, 37.3 million Americans (11.5% of adults) suffered from chronic lung disease in 2020. Asthma affects 25 million Americans, with 5.1 million children.

Aging Population: As the world's population ages, demand for oxygen therapy is predicted to rise. The United Nations Department of Economic and Social Affairs reported that the number of people aged 65 and over is expected to reach 1.5 billion by 2050. By 2050, 1 in 6 individuals worldwide will be above the age of 65, up from 1 in 11 in 2019. The United States Census Bureau reports that over the last decade, the U.S. population aged 65 and over increased by more than a third (34.2%). By 2030, all baby boomers will be 65 or older, increasing the elderly population to one in every five residents.

Technological Advancements in Oxygen Delivery Systems: Innovations in portable and home-based oxygen therapy equipment are propelling market expansion. According to the United States Food and Drug Administration (FDA), more than 50 new oxygen therapy devices or significant modifications to existing devices were authorized between 2015 and 2020. A study published in the journal Respiratory Care discovered that the usage of portable oxygen concentrators increased from 11.5% in 2009 to 43.5% in 2018 among Medicare beneficiaries getting long-term oxygen therapy.

Key Challenges:

High Costs: Oxygen therapy is expensive, especially for long-term care, with concentrators, cylinders, refills, and supplies depleting patient funds. This financial burden causes people to postpone or skip necessary treatment, lowering health outcomes. In regions with limited healthcare resources, insufficient infrastructure and a lack of subsidies impede access to inexpensive oxygen therapy.

Reimbursement Challenges: Oxygen treatment reimbursement policies are complex and vary depending on the payer, patient condition, and equipment. This lack of consistency complicates the approval process, which delays coverage and has a negative impact on patient outcomes. Extensive paperwork requirements and precise coverage limitations generate ambiguity, making it difficult for providers to plan and budget for oxygen treatment services, thus limiting market growth.

Key Trends:

Shift Towards Home-Based Care: The oxygen therapy market is shifting toward home-based care, thanks to developments in portable concentrators and remote monitoring technology. This transition decreases hospital readmissions and encourages a patient-centered approach, making it easier and less expensive for patients to get oxygen therapy at home.

Telemedicine Integration: Telemedicine is becoming increasingly important in oxygen treatment management since it allows for remote monitoring of patient vitals, oxygen levels, and therapy adherence. Early problem detection and teleconsultations improve access to specialist treatment and resolve problems, resulting in better patient outcomes and fewer consequences.

Focus on Comfort and Convenience: The market prioritizes oxygen delivery systems that are easy to use and pleasant. Lighter, quieter, and more inconspicuous concentrators and masks are being developed to increase patient comfort and convenience and to increase treatment adherence and quality of life for patients requiring oxygen therapy.

Global Oxygen Therapy Market Regional Analysis

Here is a more detailed regional analysis of the oxygen therapy market:

North America:

According to Verified Market Research, North America is estimated to dominate during the forecast period. Chronic respiratory disorders are a major driver of oxygen therapy in North America, especially in the United States. According to the Centers for Disease Control and Prevention (CDC), 16.5 million persons in the United States (6.4%) were diagnosed with COPD in 2019. Asthma affects approximately 25 million Americans, including 7.7% of adults and 7.5% of children. The American Lung Association reports that COPD is the fourth biggest cause of death in the United States. The entire cost of COPD in the United States is expected to reach USD 49 Billion in 2020, with USD 32.1 Billion in direct medical costs.

Furthermore, the elderly population in North America is driving the demand for oxygen therapy. Statistics Canada provides the following information: In 2021, more than 7 million Canadians were 65 and older, accounting for 19% of the total population. This number is predicted to increase to 9.7 million by 2030, accounting for roughly 23% of Canada's population. According to the United States Census Bureau, the number of Americans aged 65 and over is expected to nearly double, from 52 million in 2018 to 95 million in 2060. During this time, the proportion of people aged 65 and up will increase from 16% to 23% of the total population.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. Air pollution is a major concern in many Asian Pacific countries, resulting in an increase in respiratory disorders and a greater demand for oxygen therapy. According to the World Health Organization (WHO), 9 out of every 10 persons in the Asia Pacific region are exposed to air pollution levels that represent a serious health risk. In 2019, air pollution was the cause of 4.2 million premature deaths in the region. According to the Health Effects Institute's State of Global Air 2020 study, air pollution caused 1.67 million fatalities in India in 2019 and 1.85 million deaths in China. These two countries accounted for roughly 60% of global air pollution-related deaths.

Furthermore, the Asia Pacific region's population is rapidly aging, driving up the need for oxygen therapy. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the number of elderly people (aged 65 and more) in Asia and the Pacific is predicted to more than double, from 651 million in 2020 to around 1.3 billion by 2050. By 2050, roughly a quarter of the region's population will be over the age of 65. Japan, which has the region's fastest-aging population, serves as a stark illustration. According to the Japan Statistics Bureau, 28.7% of Japan's population was 65 and over in September 2020. This percentage is expected to rise to 35.3% by 2040.

Global Oxygen Therapy Market: Segmentation Analysis

The Oxygen Therapy Market is segmented on the basis of Product, Portability, and Application.

Oxygen Therapy Market, Product

Oxygen Source Equipment

Oxygen Therapy Equipment for Cardiovascular & Thoracic Surgeries

Oxygen Concentrators

Liquid Oxygen

Oxygen Cylinders

Oxygen Delivery Devices

Oxygen Maska

Nasal Cannulas

Venturi Masks

Non-Rebreather Masks

Bag-Valve Masks

Others

Based on Product, the market is segmented into Oxygen Source Equipment and Oxygen Delivery Devices. The oxygen source equipment segment is estimated to dominate the oxygen therapy market. Oxygen concentrators, which are the primary source of oxygen delivery in a variety of situations, serve as the foundation of oxygen therapy. The rising prevalence of chronic respiratory disorders demands a steady and dependable supply of oxygen, which oxygen concentrators and other source equipment deliver. While delivery devices such as masks and cannulas are required for oxygen administration, they are considered secondary parts that rely on oxygen source equipment to work. This reliance on oxygen source equipment for key functions underpins its market dominance.

Oxygen Therapy Market, By Portability

Stationary
Portable

Based on Portability, the oxygen therapy market is divided into Stationary and Portable. The portability segment is estimated to dominate the market over the forecast period due to technology improvements that have resulted in lightweight, user-friendly portable oxygen concentrators that allow patients to live active lives while getting supplementary oxygen. The growing need for home-based care, driven by an older population and rising healthcare expenses, adds to the desire for portable choices. Furthermore, greater knowledge of the benefits of portability, such as improved patient comfort and quality of life, adds to the segment's importance.

Oxygen Therapy Market, By Application

Chronic Obstructive Pulmonary Disease
Asthma
Obstructive Sleep Apnea
Respiratory Distress Syndrome
Cystic Fibrosis
Pneumonia
Others

Based on Application, the oxygen therapy market is divided into Chronic Obstructive Pulmonary Disease, Asthma, Obstructive Sleep Apnea, Respiratory Distress Syndrome, Cystic Fibrosis, Pneumonia, and Others. The chronic obstructive pulmonary disease segment is estimated to dominate the market over the forecast period. COPD is a common chronic respiratory disorder with an increasing global patient population that needs long-term supplementary oxygen to manage symptoms and improve quality of life. The progressive nature of COPD, which worsens over time, necessitates a greater reliance on oxygen therapy as the disease proceeds. This consistent and increasing demand drives the COPD segment's dominant market share in the oxygen therapy market.

Key Players

The "Oxygen Therapy Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Linde plc, Chart Industries, Inc., Invacare Corporation, Philips Respironics, Inogen, Inc., DeVilbiss Healthcare LLC, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare, GCE Group, and Taiyo Nippon Sanso Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Oxygen Therapy Market Recent Developments
In November 2021, UNICEF collaborated with the UK government and Oxygen Colab to create a reliable oxygen concentrator for use in low-resource situations. This development occurs as an endeavor to combat the Coronavirus crisis and meet the demand for oxygen in critical care settings.
In July 2021, Belluscura (BELL) signed its first and third distribution agreements for its X-PLO2RTM portable oxygen concentrators with a durable medical equipment manufacturer.

1 INTRODUCTION OF GLOBAL OXYGEN THERAPY MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL OXYGEN THERAPY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL OXYGEN THERAPY MARKET, BY PRODUCT

5.1 Overview
5.2 Oxygen Source Equipment
- 5.2.1 Oxygen Therapy Equipment for Cardiovascular & Thoracic Surgeries
- 5.2.2 Oxygen Concentrators
- 5.2.3 Liquid Oxygen
- 5.2.4 Oxygen Cylinders
5.3 Oxygen Delivery Devices
- 5.3.1 Oxygen Maska
- 5.3.2 Nasal Cannulas
- 5.3.3 Venturi Masks
- 5.3.4 Non-Rebreather Masks
- 5.3.5 Bag-Valve Masks
5.4 Others

6 GLOBAL OXYGEN THERAPY MARKET, BY PORTABILITY

6.1 Overview
6.2 Stationary
6.3 Portable

7 GLOBAL OXYGEN THERAPY MARKET, BY APPLICATION

7.1 Overview
7.2 Chronic Obstructive Pulmonary Disease
7.3 Asthma
7.4 Obstructive Sleep Apnea
7.5 Respiratory Distress Syndrome
7.6 Cystic Fibrosis
7.7 Pneumonia
7.8 Others

8 GLOBAL OXYGEN THERAPY MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL OXYGEN THERAPY MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Linde plc
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Chart Industries, Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Invacare Corporation
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Philips Respironics
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Inogen, Inc
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 DeVilbiss Healthcare LLC
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Fisher & Paykel Healthcare Limited
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Drive DeVilbiss Healthcare
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 GCE Group
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Taiyo Nippon Sanso Corporation.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments